Opinion

Video

The Benefits of Multidisciplinary Care in Prostate Cancer Management

Author(s):

Eleni Efstathiou, MD, PhDSean Collins, MD, PhD

Panel discusses how collaboration between specialties improves patient outcomes.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
Ruben Olivares, MD
Related Content
US FDA
September 3rd 2024

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
August 27th 2024

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Kara N. Maxwell, MD, PhD, director, Men and BRCA Program, Basser Center, associate professor, medicine (hematology-oncology), Perelman School of Medicine, University of Pennsylvania
August 20th 2024

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 16th 2024

Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC